- Home
- Automated
- List of product information
- TOLTERODINE MEVON SR CAPSULE 2 MG [SIN16433P]
TOLTERODINE MEVON SR CAPSULE 2 MG [SIN16433P]
Active ingredients: TOLTERODINE MEVON SR CAPSULE 2 MG
Product Info
TOLTERODINE MEVON SR CAPSULE 2 MG
[SIN16433P]
Product information
Active Ingredient and Strength | TOLTERODINE TARTRATE - 2 MG |
Dosage Form | CAPSULE, EXTENDED RELEASE |
Manufacturer and Country | PHARMATHEN INTERNATIONAL S.A - GREECE |
Registration Number | SIN16433P |
Licence Holder | NOVEM PHARMA PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | G04BD07 |
4.1 Therapeutic indications
Tolterodine is indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.
4.2 Posology and method of administration
The extended-release capsules can be taken with or without food and must be swallowed whole (see Section 5.2 – Pharmacokinetic Properties, Pharmacokinetic characteristics – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Adults (including the Elderly)
The recommended total daily dose is 4 mg. Dosage with tolterodine capsules is 4 mg once daily. The total daily dose may be reduced to 2 mg, based on individual tolerability.
Use in Children
Safety and effectiveness in children have not yet been established.
Use in Impaired Renal Function
The recommended total daily dose is 2 mg (i.e., tolterodine capsules 2 mg once daily) for patients with impaired renal function (see Section 4.4 – Special Warnings and Precautions for Use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Use in Impaired Hepatic Function
The recommended total daily dose is 2 mg (i.e., tolterodine capsules 2 mg once daily) for patients with impaired hepatic function (see Section 4.4 – Special Warnings and Precautions for Use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Use with Potent CYP3A4 Inhibitors
The recommended total daily dose is 2 mg (i.e., tolterodine capsules 2 mg once daily) for patients receiving concomitant ketoconazole or other potent CYP3A4 inhibitors (see Section 4.4 – Special Warnings and Precautions for Use, CYP3A4 inhibitors, and Section 4.5 – Interactions with Other Medicinal Products and Other Forms of Interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
4.3 Contraindications
Tolterodine is contraindicated in patients with:
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information
Urinary retention
Uncontrolled narrow angle glaucoma
